EDITORIAL

GERIATRICS IN THE 21ST CENTURY

B. VELLAS1, J.E. MORLEY2

1. Gérontopôle, Centre Hospitalier Universitaire de Toulouse, Toulouse, France; 2. Division of Geriatric Medicine, Saint Louis University School of Medicine, St. Louis, Missouri USA.

Over this century we can expect to see older persons live longer, be more resilient and less frail.

Research and care have been built to identify and treat diseases, but not to maintain functional capacities (eg, mobility, cognition, immune functions, etc.) during aging. As a consequence, individuals do not receive the healthcare they need to prevent/delay the onset of dependency (an almost irreversible and economically burdensome condition). For the W.H.O (1, 2), healthy aging is not a life without diseases, we have diseases at any age, but it is a life where we are able to maintain the functions we need to be able to do what we value.

To make it possible we will have to:

- identify biological profiles predictive of functional loss, and to discover, validate, and implement innovative rejuvenative strategies for delaying age-related functional loss (3);
- to increase functional reserves in early aging (50-70yrs) and prevent declines in functions and recover impaired functions in late aging (70 yrs or over);
- to translate the innovative procedures, tools and products into a new care model for aging populations using new technologies (ICT solutions);
-智能计算机 (18).

One of the tasks of the geriatrician will be to undertake the stewardship of the emerging “senolytics” and determine for whom and at what stage prescribing these drugs is appropriate (4). Clustered Regularly Interspaced Short Palendromic Repeats (CRISPR/Cas9) genomic editing will be mainly used to eradicate congenital diseases at the embryonic stage before birth, but using an adenovirus vector, techniques will emerge to treat sarcopenia, frailty and dementia in older persons (5). This is already being done for the treatment of some cancers (6). An example that should develop over the next decade is using CRISPR/Cas9 to silence the myostatin gene (7). The rapid development of biological drugs will require the geriatrician to be an expert on these emerging drugs and their side-effects, e.g., antibodies against myostatin or activin receptors to treat sarcopenia (8). Geriatricians are already aware of the problems produced by polypharmacy and inappropriate drug use in older persons (9-17), and this will only become worse with the interactions with biologics which will only become obvious after many years of use. All of this will drive geriatricians to become prime users of personalized (P4) medicine (i.e., predictive, preventive, personalized and participatory), assisted by computers (18).

The other area in which geriatricians will need to develop new skills will be in disruptive technology (19-21). The ability of older persons to “age-in-place” will be highly dependent on home electronic monitoring and the availability of robots such as “companionable” (22-24). Exoskeletons and other devices will allow persons who are functionally impaired to be able to continue to function (25-27). Telemedicine will become central to providing home care (28-30). Entertainment robots, such as Paro and Aibo (31-34) and exercise robotic trainers will become important for elder care (35).

Many geriatricians will focus on being geriatric hospitalists providing care for persons over 70 years in hospital, balancing the need for maintaining function as well as treating disease, as is done in Acute Care for the Elderly (ACE) units (36). Geriatricians will play a key role in enhancing care for older persons with hip fractures (37-40), trauma (41, 42), delirium, utilizing Delirium Intensive Care Units and other techniques (43-46), and stroke patients (47, 48). Working with dietitians they will have a specific role on preventing and treating undernutrition and cachexia in the hospital setting (49-53).

Modern Geriatric Giants

A major role of the geriatrician will be to train family practitioners to recognize and where possible provide care for the major geriatric syndromes, i.e., frailty, sarcopenia, anorexia of aging and cognitive dysfunction (54). Already a number of approaches have been developed to increase awareness of these syndromes (55, 56). These approaches include the Kihon Index (57, 58), EasyCare (59, 60), Vulnerable Elder Survey (61), the Gerontopole Frailty Index (62-65), and the Rapid Geriatric Assessment (66, 67).

-Frailty has become central to geriatric syndromes, either as the physical phenotype (68, 69), or as the Frailty Co-morbidity Index (70, 71). Studies have suggested that exercise and nutrition interventions can improve outcomes in frail older persons (72-75). A rapid screen – the FRAIL – can be utilized both in hospitals (76, 77) and in the outpatient setting (78-81). A computerized algorithm has been developed to allow health professionals to recognize and treat frailty (82). The Asia Pacific Conference has developed guidelines for the treatment of frailty (83). A Mediterranean diet and polyphenols appear to decrease the chance of developing frailty (84-87).

A number of definitions for sarcopenia have been developed.
They all recognize that it consists of poor function (walking speed or grip function) in the presence of low muscle mass (88–93). The primary treatment consists of resistance exercise (94–98). Leucine enriched essential amino acids (whey protein) or possibly hydroxymethyl butyrate are the treatment of choice to act synergistically with exercise through direct stimulation of mTOR (99–103). The SARC-F is a quick screen that is available for use by primary care professionals (104–107).

It is now well recognized that the anorexia of aging puts older persons at risk for weight loss and undernutrition (108,109). Numerous studies have shown that the MNA is an excellent screening test for malnutrition (110–118). The SNAQ has been shown to be a reasonable test to predict anorexia and identify persons at risk of weight loss (119–122). The MEALS-ON-WHEELS mnemonic provides the major reversible causes of weight loss (123). Cachexia is predominantly due to inflammatory cytokines (124, 125). It can be recognized, using the Glasgow Cachexia Scale, by finding a low albumin and an elevated CRP (126). Anamorelin, a ghrelin agonist, increases food intake and muscle mass but not function in persons with cachexia (127).

There are numerous causes of cognitive dysfunction and dementia. The three most common causes of dementia are Alzheimer’s disease (45%), vascular dementia (32%) and Lewy-Body Dementia (10%) (128). There are a number of reversible causes of mild cognitive impairment and early dementia (129). A Mediterranean diet with extra virgin olive oil delays the loss of cognition and may prevent Alzheimer’s disease (130–132). A number of other nutritional approaches have been tried with limited success (133–136). Dementia has decreased in the USA most probably because of increased treatment of cardiovascular risk factors (137). At present, the drugs available to treat Alzheimer’s disease have been somewhat disappointing. With the new imaging techniques giving an improved diagnosis of Alzheimer’s diseases, it is hoped that new drugs will be developed to improve treatment. Antisenses (oligonucleotides) to Amyloid Precursor Protein are one class of drug with positive effects in animals that have yet to be tested in humans (138, 139). The recent recognition of the “diabetic brain” as a unique cause of cognitive loss opens up the possibility of new drugs to treat this condition (140). The Rapid Cognitive Screen (RCS) has been shown to be an excellent, quick screening test for mild cognitive impairment and dementia (141). Cognitive Stimulation Therapy has shown promise in treating moderate dementia (142–145). The recognition and management of cognitive frail will be a major area in this century (146–152).

Long-Term Care

The improvement of the quality of care and long-term care research, as well as better recognition for the health care professionals who work in this arena is clearly an important role of the geriatrician (153, 154). A research agenda has been set by the IAGG-GARN nursing home group (155). The FRAIL-NH has been shown to be an excellent tool for recognizing those at major risk of poor outcomes (156). The use of advanced practice nurses in this arena is likely to greatly improve quality of care (157). It has been suggested that nursing homes may be excellent venues to provide exercise therapy and other support for community living adults (158).

Conclusion

It is likely that this century will produce many exciting and unimaginable improvements in care for the aging population. As an example, in 1917, no one imagined the existence of penicillin which was only discovered 11 years later. Geriatricians will need to keep up to date with numerous biochemical and pharmaceutical studies while continuing to recognize the need to focus on person centered care and to develop new systems, if we are to remain the “Superspecialists” that we are today (159). It is to be hoped that this century will be “the best of times…an epoch of incredulity…and a spring of hope.”

It is our hope that the Journal of Nutrition Health and Aging will be a beacon leading geriatricians and other health professionals into this exciting new world which will increase resilience and decrease frailty in the aging population.

References

1. Beard JR, Officer A, de Carvalho IA, Sadana R, Pot AM, Michel JP, et al. The World Report on Ageing and Health: A policy framework for healthy ageing. Lancet 2016;387(10033):2145–2154.
2. World Health Organization. 2017. Integrated Care for Older People: Guidelines on Community-level interventions to manage declines in intrinsic capacity. Geneva: World Health Organization. License CC By-NC-SA 3.0 IGO.
3. Eming SA, Syan TA, Martin P. Inflammation and metabolism in tissue repair and regeneration. Science 2017;256: 1026–1030.
4. Kirkland JL, Tchkonia T, Zhu Y, et al. (2017) The clinical potential of senolytic drugs. J Am Geriatr Soc Sep 2017; doi:10.111/jgs.14969 [Epub ahead of print].
5. Musumura K. The hope and hype of CRISPR-Cas9 genome editing: A review. JAMA Cardiol 2017;2(8):914–919.
6. Liu C, Zhang L, Liu H, Cheng K. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J Control Release 2017;Sep 11. doi:10.1016/j.jconrel.2017.09.012 [Epub ahead of print].
7. Wei Y, Chen Y, Qiu Y, Zhao H, Liu G, Zhang Y, et al. Prevention of muscle wasting by CRISPR/Cas9-mediated disruption of myostatin in vivo. Mol Ther 2016;24:1889–1891.
8. Vellas B, Fielding R, Bhasin S, et al. Sarcopenia trials in specific diseases: Report by the international conference on frailty and sarcopenia research task force. J Frailty Aging 2016;5(4):194–200.
9. Rolland Y, Morley JE. Editorial: Frailty and polypharmacy. J Nutr Health Aging 2016;20:645–646.
10. Veronese N, Stubbs B, Noale M, et al. Polypharmacy is associated with higher frailty risk in older people: An 8-year longitudinal cohort study. J Am Med Dir Assoc 2017;18:624–628.
11. Cherubini A, Corsonello A, Lattanzio F. Polypharmacy in nursing home residents: What is the way forward? J Am Med Dir Assoc 2016;17:4–6.
12. Poudel A, Peel NM, Nissen LM, et al. Adverse outcomes in relation to polypharmacy in robust and frail older hospital patients. J Am Med Dir Assoc 2016;17:767–767.e13.
13. Morley JE. Inappropriate drug prescribing and polypharmacy are major causes of poor outcomes in long-term care. J Am Med Dir Assoc 15(1):780–782.
14. Jokanovic N, Tan EC, Dooley MJ, et al. Prevalence and factors associated with polypharmacy in long-term care facilities: A systematic review. J Am Med Dir Assoc 2015;6:535.e1–12.
15. Little MO, Morley A. Reducing polypharmacy: Evidence from a simple quality improvement initiative. J Am Med Dir Assoc 2013;14:152–156.
Geriatricians in the 21st Century

16. Morley JE. Polypharmacy in the nursing home. J Am Med Dir Assoc 2009;10:289-291.

17. Schepisi R, Fusco S, Sganga F, Falcone B, Vettrano DL, Abbatecola A, et al. Inappropriate use of protein pump inhibitors in elderly patients discharged from acute care hospitals. J Nutr Health Aging 2016;20:665-670.

18. Morley JE, Vellas B. Patient-centered (P4) medicine and the older person. J Am Med Dir Assoc 2017;18(6):457-459.

19. Michel JP, Franco A. Geriatricians and technology. J Am Med Dir Assoc 2014;15:860-862.

20. Piuu A, Campo E, Rumeau P, et al. Aging society and gerontechnology: A solution for an independent living? J Nutr Health Aging 2014;18(8):97-112.

21. Mulvenna J, Hotton A, Coates V, et al. Views of caregivers on the ethics of assistive technology used for home surveillance of people with dementia. Neuroethics 2017;10:255-266.

22. Lattanzio F, Abbatecola AM, Bevilacqua R, et al. Advanced technology care innovation for older people in Italy: Necessity and opportunity to promote health and wellbeing. J Am Med Dir Assoc 2014;15:457-466.

23. Rantz M, Phillips LJ, Galambos C, et al. Randomized trial of intelligent sensor system for early illness alerts in senior housing. J Am Med Dir Assoc 2017;Jul 12. Doi: 10.1016/j.jamda.2017.05.012 [Epub ahead of print].

24. Little MO, Rantz M, Lynn GA. Health information technology in long-term care: Potential for the future. J Am Med Dir Assoc 2016;17:379-380.

25. Lattanzio F, Abbatecola AM, Bevilacqua R, et al. Advanced technology care innovation for older people in Italy: Necessity and opportunity to promote health and wellbeing. J Am Med Dir Assoc 2014;15:457-466.

26. Hall A, Wither CB, Eilertsen E, Todd C. Implementing monitoring technologies in care homes for people with dementia: A qualitative exploration using Normalization Process Theory. Int J Nurs Stud 2017;72:60-70.

27. Lee DJ, Bae SJ, Jang SH, Chang PH. Design of a clinically relevant upper-limb exoskeleton robot for stroke patients with spasticity. IEEE Int Conf Rehabil Robot Jul 2012;622-627. Doi: 10.1109/IORR.2012.6309317.

28. Morley JE. Telemedicine: Coming to nursing homes in the near future. J Am Med Dir Assoc 2016;17:1-3.

29. Hui E, Woo J, Hjelm M, et al. Telemedicine: A pilot study in nursing home residents. Gerontology 2001;56:47-57.

30. Volcier L. Nursing home telepsychiatry. J Am Med Dir Assoc 2015;16:7-8.

31. Banks WA. Artificial emotions: Robots caring for the elderly: J Am Med Dir Assoc 2014;15:457-466.

32. Moyle W, Jones C, Murfield JE, et al. Use of a robotic seal as a therapeutic tool to improve dementia symptoms: A cluster-randomized controlled trial. J Am Med Dir Assoc 2017;18:766-773.

33. Beemelmanns R, Gelderblom GJ, Jonker P, de Witte L. Socially assistive robots in elderly care: A systematic review into effects and effectiveness. J Am Med Dir Assoc 2016;17:313-329.

34. Egan KJ, Pot AM. Encouraging innovation for assistive health technology in dementia: Barriers, enablers and next steps to be taken. J Am Med Dir Assoc 2016;17:357-363.

35. Aoyagi D, Ichinose WV, Harkema SJ, Reinkensmeyer DJ, Bobrow JE. A robot and computer algorithm that can successfully assist in naturalistic muscle during body-weight-supported gait training following neurologic injury. IEEE Trans Neural Syst Rehabil Eng 2007;15:387-400.

36. Landefeld CS, Palmer RM, Kresevic DM, Fortinsky RH, Kowal J. A randomized trial of care in a hospital medical unit especially designed to improve the functional outcomes of acutely ill older patients. N Engl J Med 1995;332:1349-1344.

37. Abrahamsen C, Norgaard B, Draborg E, Nielsen D. Reflections on two years after experience of the Gerontopole. Vellas B. J Nutr Health Aging 2015;19:673-680.

38. Arora VM, Johnson M, Olson J, Podrazik PM, Levine S, Dubeau CE, et al. Using assessment care of vulnerable elders quality indicators to measure quality of hospital care for vulnerable elders. J Am Geriatr Soc 2007;55:1705-1711.

39. Vellas B. Implementing frailty screening, assessment, and sustained intervention: The experience of the Gerontopole. Vellas B J Nutr Health Aging 2015;19:673-680.

40. Lattanzio F, Abbatecola AM, Gierveld R, et al. Description of 1,108 older patients with frailty assessed by Fried and Kihon checklist indexes in a prospective cohort study: Design and demographics of the Kyoto-Kameoka Longitudinal study. J Am Med Dir Assoc 2017;18:733.e7-733.e15.

41. Kera T, Kawai H, Yoshida H, Kirano H, Kojima M, Fujiwara Y, et al. Classification of frailty using the Kihon checklist: A cluster analysis of older adults in urban areas. Agerut Gerontol Int 2017;17:69-77.

42. Brandao MP, Martins L, Pires MA, Cardoso MF. Reliability and validity of the EASYCare-2010 standard to assess elderly people in Portuguese primary health care. Aten Primaria Apr 2017;5:doi: 10.1016/j.aprim.2016.11.006 [Epub ahead of print].

43. Geessink NH, Schoon Y, Olde Rikkert MG, Melis RJ. Criterion validity of a frailty index derived from the EASYcare instrument. J Am Geriatr Soc 2017;65:222-224.

44. Arora VM, Johnson M, Olson J, Podrazik PM, Levine S, Dubeau CE, et al. Using assessment care of vulnerable elders quality indicators to measure quality of hospital care for vulnerable elders. J Am Geriatr Soc 2007;55:1705-1711.

45. Vellas B. Implementing frailty screening, assessment, and sustained intervention: The experience of the Gerontopole. Vellas B J Nutr Health Aging 2015;19:673-680.

46. Lattanzio F, Abbatecola AM, Gierveld R, et al. Description of 1,108 older patients with frailty assessed by Fried and Kihon checklist indexes in a prospective cohort study: Design and demographics of the Kyoto-Kameoka Longitudinal study. J Am Med Dir Assoc 2017;18:733.e7-733.e15.

47. Arora VM, Johnson M, Olson J, Podrazik PM, Levine S, Dubeau CE, et al. Using assessment care of vulnerable elders quality indicators to measure quality of hospital care for vulnerable elders. J Am Geriatr Soc 2007;55:1705-1711.

48. Geessink NH, Schoon Y, Olde Rikkert MG, Melis RJ. Criterion validity of a frailty index derived from the EASYcare instrument. J Am Geriatr Soc 2017;65:222-224.

49. Arora VM, Johnson M, Olson J, Podrazik PM, Levine S, Dubeau CE, et al. Using assessment care of vulnerable elders quality indicators to measure quality of hospital care for vulnerable elders. J Am Geriatr Soc 2007;55:1705-1711.

50. Vellas B. Implementing frailty screening, assessment, and sustained intervention: The experience of the Gerontopole. Vellas B J Nutr Health Aging 2015;19:673-680.

51. Lattanzio F, Abbatecola AM, Gierveld R, et al. Description of 1,108 older patients with frailty assessed by Fried and Kihon checklist indexes in a prospective cohort study: Design and demographics of the Kyoto-Kameoka Longitudinal study. J Am Med Dir Assoc 2017;18:733.e7-733.e15.

52. Kera T, Kawai H, Yoshida H, Kirano H, Kojima M, Fujiwara Y, et al. Classification of frailty using the Kihon checklist: A cluster analysis of older adults in urban areas. Agerut Gerontol Int 2017;17:69-77.

53. Brandao MP, Martins L, Pires MA, Cardoso MF. Reliability and validity of the EASYCare-2010 standard to assess elderly people in Portuguese primary health care. Aten Primaria Apr 2017;5:doi: 10.1016/j.aprim.2016.11.006 [Epub ahead of print].

54. Geessink NH, Schoon Y, Olde Rikkert MG, Melis RJ. Criterion validity of a frailty index derived from the EASYcare instrument. J Am Geriatr Soc 2017;65:222-224.

55. Arora VM, Johnson M, Olson J, Podrazik PM, Levine S, Dubeau CE, et al. Using assessment care of vulnerable elders quality indicators to measure quality of hospital care for vulnerable elders. J Am Geriatr Soc 2007;55:1705-1711.

56. Vellas B. Implementing frailty screening, assessment, and sustained intervention: The experience of the Gerontopole. Vellas B J Nutr Health Aging 2015;19:673-680.

57. Lattanzio F, Abbatecola AM, Gierveld R, et al. Description of 1,108 older patients with frailty assessed by Fried and Kihon checklist indexes in a prospective cohort study: Design and demographics of the Kyoto-Kameoka Longitudinal study. J Am Med Dir Assoc 2017;18:733.e7-733.e15.

58. Arora VM, Johnson M, Olson J, Podrazik PM, Levine S, Dubeau CE, et al. Using assessment care of vulnerable elders quality indicators to measure quality of hospital care for vulnerable elders. J Am Geriatr Soc 2007;55:1705-1711.

59. Vellas B. Implementing frailty screening, assessment, and sustained intervention: The experience of the Gerontopole. Vellas B J Nutr Health Aging 2015;19:673-680.
randomized controlled trial. J Am Med Dir Assoc 2012;13:24-30.
74. Tarazona-Santabalbina FJ, Gomez-Cabreria MC, Perez-Ros P, Martinez-Amea FM, Carbo H, Tsaparas K, et al. A multimorbidity intervention that reverses frailty and improves cognition, emotion, and social networking in the community-dwelling frail elderly: A randomized clinical trial. J Am Med Dir Assoc 2016;17:426-433.
75. Ahrenda P, Lopez MD, Garcia VP, Estrella Jde D, da Silva Gonzalez A, Villardell NB, Torres KA. Effects of an oral nutritional supplementation plus physical exercise intervention on the physical function nutritional status, and quality of life in frail institutionalized older adults: The ACTIVINES study. J Am Med Dir Assoc 2015;16:639.e49-56.
76. Gleeson LJ, Benton EA, Alvarez-Nebreda ML, Weaver MJ, Harris MB, Javedan H. FRAIL questionnaire screening tool and short-term outcomes in geriatric fracture patients. J Am Med Dir Assoc Aug 2017;30 doi: 10.1016/j.jamda.2017.07.005 [Epub ahead of print].
77. Chong E, Ho E, Baldevraona-Liego J, Chan M, Wu L, Tay L. Frailty and risk of adverse outcomes in hospitalized older adults: A comparison of different frailty measures. J Am Med Dir Assoc 2017;18:638.e7-638.e11.
78. Van Kan GA, Rolland Y, Bergman H, et al. The IANA task force on frailty assessment of older people in clinical practice. J Nutr Health Aging 2008;12(1):29-37.
79. Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging 2016;19:601-608.
80. Woo J, Jo R, Wong M, et al. Frailty screening in the community using the FRAIL scale. J Am Med Dir Assoc 2015;16:412-419.
81. Gleeson LJ, Benton EA, Alvarez-Nebreda ML, et al. FRAIL questionnaire screening tool and short-term outcomes in geriatric fracture patients. J Am Med Dir Assoc 2017;Assoc 18:___-___ (Dec).
82. Malmstrom TK, Miller DK, Morley JE. A comparison of four frailty models. J Am Geriatr Soc 2014;62:721-726.
83. Dent E, Lien C, Lim WS, et al. The Asia-Pacific Clinical Practice Guidelines for the management of frailty. J Am Med Dir Assoc 2015;17(8):564-575.
84. Leon-Munoz LM, Guallar-Castillon P, Lopez-Garcia E, Rodriguez-Artalejo F. Mediterranean diet and risk of frailty in community-dwelling older adults. J Am Med Dir Assoc 2014;15:899-903.
85. Bonnefoy M, Berrut G, Lesourd B, Ferry M, Gilbert T, Guerin O, et al. Frailty and nutrition: Searching for evidence. J Nutr Health Aging 2015;19:250-257.
86. Urpi-Sarda M, Andres-Lacueva C, Rabassa M, Ruggiero C, Zamora-Ros R, Bandini S, et al. The relationship between urinary total polyphenols and the FRAIL Phenotype in a community-dwelling older population: The InCHIANTI study. J Gerontol A Biol Sci Med Sci 2015;70:1141-1147.
87. Veronese N, Stubbs B, Noale M, Solmi M, Rizziello V, Vaona A, et al. Adherence to a Mediterranean diet is associated with lower incidence of frailty: A longitudinal cohort study. Clin Nutr Sep 2017;4 doi:10.1016/j.clnu.2017.08.028 [Epub ahead of print].
88. Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: An undiagnosed condition in older adults. Current consensus definition, Prevalence, etiology, and consequences. International Working Group on Sarcopenia. J Am Med Dir Assoc 2011;12(4):249-256.
89. Morley JE, Abbatecola AM, Argiles JM, et al. Society on Sarcopenia, Cachexia and Wasting Disorders Trialist Workshop. Sarcopenia and limited mobility: An international consensus. J Am Med Dir Assoc 2011;12(6):403-409.
90. Chen LK, Liu LW, Woo J, et al. Sarcopenia in Asia: Consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 2014;15:95-101.
91. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010;39:412-423.
92. Cruz-Jentoft AJ, Landi F, Schneider SM, Zuniga C, Arzi H, Boirie Y, et al. Prevalence of an interventions for sarcopenia in ageing adults: A systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing 2014;43:748-759.
93. Vellas B, Fielding R, Bhasin S, Cerretta F, Goodpaster B, Guralnik JM, et al. Sarcopenia trials in specific diseases: Report by the International Conference on Frailty and Sarcopenia Research Task Force. J Frailty Aging 2015;4:194-200.
94. Weisberger KD, Cadow DG, Farthing JP. Whey protein and high-volume resistance training in postmenopausal women. J Nutr Health Aging 2015;19:511-517.
95. Rolland Y, Czerwinski S, van Kan GA, et al. Sarcopenia: Its assessment, etiology, pathogenesis-, consequences and future perspectives. J Nutr Health Aging 2008;12(7):433-450.
96. Morley JE. Sarcopenia: Diagnosis and treatment. J Nutr Health Aging 2008;12(7):452-456.
97. Tieland M, Derks ML, van der Zwaluw N, Verdijk LB, van de Rest O, de Groot LC, van Loon LJ. Protein supplementation increases muscle mass gain during prolonged resistance-type exercise training in frail elderly people: A randomized, double-blind, placebo-controlled trial. J Am Med Dir Assoc 2012;13:713-719.
98. Chuchward-Venne TA, Tieland M, Verdijk LB, et al. There are no nonresponders to resistance-type exercise training in older men and women. J Am Med Dir Assoc 2015;16:400-411.
127. Anker SD, Coats AJ, Morley JE. Evidence for partial pharmaceutical reversal of the cancer anorexia-cachexia syndrome: The case of anamorelin. J Cachexia Sarcopenia Muscle 2015;5:275-277.

128. Cholerton B, Larson EB, Baker LD, Craft S, Crane PK, Millard SP, et al. Neuropathologic correlates off cognition in a population-based sample. J Alzheimers Dis 2013;36:699-709.

129. Morley JE. Mild cognitive impairment—a treatable condition. J Am Med Assoc 2014;1(1):1-5.

130. Martinez-Lapiscina EH, Clavero P, Toledao E, et al. Virgin olive oil supplementation and long-term cognition: The Predimed-Navarra randomized, trial. J Nutrl Health Aging 2013;17(6):544-552.

131. Farr SA, Price TO, Dominguez LJ, Motisi A, Saiano F, Niehoff ML, et al. Extra virgin olive oil improves learning and memory in SAMP8 mice. J Alzheimers Dis 2012;28:81-92.

132. Solfrizzi V, Castodero C, Lozupone M, Imbimbo BP, Valiani V, Agosti P, et al. Relationships of dietary patterns, foods, and macro- and macronutrients with Alzheimer’s disease and late-life cognitive disorders: A systematic review. J Alzheimers Dis 2017;59:815-849.

133. Salva A, Andrieu S, Fernandez E, Schiffin RJ, Moulin J, Decarli B, et al. Health and nutrition promotion program for patients with dementia (NutriAlz): Cluster randomized trial. J Nutrl Health Aging 2011;15:822-830.

134. Shah R. The role of nutrition and diet in Alzheimer disease: A systematic review. J Am Med Dir Assoc 2013;14:398-402.

135. Bourre JM. Dietary omega-3 fatty acids and psychiatry: Mood, behavior, stress, depression, dementia and aging. J Nutrl Health Aging 2005;9(1):31-38.

136. Ferry M, Coley N, Andrieu S, Bonhomme C, Caubere JP, Cesari M, et al. How to design nutrition intervention trials to slow cognitive decline in apparently healthy populations and apply for efficacy claims: A statement from the International Academy on Nutrition and Aging Task Force. J Nutrl Health Aging 2013;17:619-623.

137. Langa KM, Larson EB, Crimmins EM, Fual JD, Levine DA, Kabeto MU, Weir DR. A comparison of the prevalence of dementia in the United States in 2000 and 2012. JAMDA Intern Med 2017;17:51-58.

138. Morley JE, Farr SA, Kumar VB, Armbrrecht HJ. The SAMP8 mouse: A model to develop therapeutic interventions for Alzheimer’s disease. Curr Pharm Des 2012;18:1123-1130.

139. Morley JE, Armbrrecht HJ, Farr SA, Kumar VB. The senesence accelerated mouse (SAMP8) as a model for oxidative stress and Alzheimer’s disease. Biochim Biophys Acta 2012;1822:650-656.

140. Morley JE. Diabetes: The diabetic brain. Nat Rev Endocrinol 2017;13:570-571.

141. Malmstrom TK, Voss VB, Cruz-Oliver DM, Cummings-Vaughn LA, Tumosa N, Grossberg GT, Morley JE. The rapid cognitive screen (RCS): A point-of-care screening for dementia and mild cognitive impairment. J Nutrl Health Aging 2015;19:741-744.

142. Berg-Weger M, Teeb S, Henderson-Kalb J, Zubatsky M, Lundy J, Hayden D. Cognitive stimulation therapy: A tool for your practice with persons with dementia? J Am Med Dir Assoc 2015;16:795-796.

143. D’Amico F, Rehill A, Knapp M, Aguirre E, Donovan H, Hoare Z, et al. Maintenance cognitive stimulation therapy: An economic evaluation within a randomized controlled trial. J Am Med Dir Assoc 2015;16:63-70.

144. Loraine J, Taylor S, McAllister M. Cognitive and physical stimulation therapy. J Am Med Dir Assoc 2014;15:140-141.

145. Morley JE, Cruz-Oliver DM. Cognitive stimulation therapy. J Am Med Dir Assoc 2014;15:689-691.

146. Rippopo M, Mulasso A, Rabaglietti E. Cognitive frailty in Italian community-dwelling older adults: Prevalence rate and its association with disability. J Nutrl Health Aging 2017;21:631-636.

147. Sargent L, Brown R. Assessing the current state of cognitive frailty: Measurement properties. J Nutrl Health Aging 2017;21:152-160.

148. Shimada H, Makizako H, Lee S, Doi T, Lee S, Tsutsunimoto K, et al. Impact of cognitive frailty on daily activities in older persons. J Nutrl Health Aging 2016;20:729-735.

149. Tay L, Lim WS, Chan M, Ye RJ, Chong MS. The independent role of inflammation in physical frailty among older adults with mild cognitive impairment and mild-to-moderate Alzheimer’s disease. J Nutrl Health Aging 2016;20:288-299.

150. Halli L, Cemal Kizilarslanoglu M, Emin Kuyumcu M, Yesil Y, Cruz-Jentoft AJ. Cognitive aspects of frailty: Mechanisms behind the link between frailty and cognitive impairment. J Nutrl Health Aging 2015;19:276-283.

151. Canevelli M, Cesari M. Cognitive frailty: What is still missing? J Nutrl Health Aging 2015;19:273-275.

152. Kalaaiditi E, Cesari M, Canevelli M, et al. (2013) Cognitive frailty: Rational and definition from an (IAMA/IAGG) International consensus group. J Nutrl Health Aging 2013;17(9):726-734.

153. Rolland Y, Tolson D, Morley JE, Vellas B. The International Association of Gerontology and Geriatrics (IAGG) nursing home initiative. J Am Med Dir Assoc 2014;15:307-308.

154. Tolson D, Rolland Y, Andrieu S, et al. The International Association of Gerontology and Geriatrics: A global agenda for clinical research and quality of care in nursing homes. J Am Med Dir Assoc 2011;12:184-189.

155. Morley JE, Caplan G, Cesari M, et al. International survey of nursing home research priorities. J Am Med Dir Assoc 2014;15:309-312.

156. Kaehr EW, Pape LC, Malmstrom TK, Morley JE. FRAIL-NH predicts outcomes in long term care. J Nutrl Health Aging 2016;20:192-198.

157. Laffon de Mazieres C, Morley JE, Levy C, et al. Prevention of functional decline by reframing the role of nursing homes? J Am Med Dir Assoc 2017;18(2):105-110.

158. de Souza Barreto P, Vellas B, Morley JE, et al. The nursing home population: An opportunity to make advances on multimorbidity and polypharmacy. J Nutrl Health Aging 2013;17(4):399-400.

159. Morley JE. Geriatricians: The super specialists. J Am Geriatr Soc 2017;65(4):866-868.